RE:Real story?
There is more substance to that article that I posted than what I have heard from Friessen in years. He is usually "under the radar" for the most part. My biggest question...why would you give a branded trade name to a generic? Never has been done before. Is this a patented formulation? Friessen listed advantages...is this for all pitavastatin meds? or is Zypitamag a one-off? I'm am merely guessing, but I "think" that mph's windfall from the apicore deal is going to broadening the sales force with these partnerships. If that's the case, friessen's strategy just might work. I'm more optimistic.